What's Happening?
AGC Biologics has partnered with Rarity PBC to provide development and GMP manufacturing for RDP-101, a gene therapy aimed at treating Adenosine Deaminase Severe Combined Immunodeficiency Disorder (ADA-SCID).
This rare condition severely compromises the immune system, leaving infants vulnerable to infections. The partnership involves comprehensive services to bring the therapy to market, utilizing AGC Biologics' ProntoLVV platform. If approved by the FDA, RDP-101 would be the first gene therapy for ADA-SCID available commercially in the US, offering hope to affected families.
Why It's Important?
The collaboration between AGC Biologics and Rarity PBC marks a critical advancement in the treatment of ADA-SCID, a life-threatening genetic disorder. By leveraging AGC Biologics' expertise in gene therapy manufacturing, the partnership aims to make RDP-101 accessible to patients in need. This development could significantly improve the quality of life for individuals with ADA-SCID, reducing the risk of severe infections. The successful commercialization of RDP-101 may also pave the way for further innovations in gene therapy, potentially benefiting patients with other rare genetic disorders.
